Cubist wins FDA nod for antibiotic Zerbaxa
This article was originally published in Scrip
Before its acquisition of Cubist Pharmaceuticals was barely underway, Merck's 9.5bn bid for the company already has garnered it a nice payoff – the US approval on 19 December of Zerbaxa (ceftolozane/tazobactam), a new combination antibiotic intended to treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).
You may also be interested in...
Merck unveiled Phase III data showing efficacy in hospital-acquired bacterial pneumonia, but branded drugs with this indication currently have not scored significant sales.
Company presents game plan for targeting 1,900 high-prescribing hospitals in US in a launch kicking off in the second half of October.
The Medicines Co. is a few years behind its most recent beta-lactamase inhibitor competitors, but its antibiotic Carbavance is the only one with pivotal data that show superiority to a well-known drug in the same class for the treatment of hospital-based urinary tract infections.